This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.62% per year. These returns cover a period from January 1, 1988 through June 2, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
biotechnology: Archive
PRTA Dives 53.5% YTD: Will the Restructuring Effort Boost Prospects?
by Zacks Equity Research
Prothena slashes 63% of its workforce and axes birtamimab after trial failure, reshaping its pipeline and financial outlook. Shares plunge 53.5% YTD.
RHHBYNegative Net Change BMYNegative Net Change NVONegative Net Change PRTAPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy WisdomTree, Inc. (WT) After Golden Cross?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
WTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Vertiv Holdings Co. (VRT)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
VRTPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy WSFS Financial (WSFS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
WSFSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy 1st Source (SRCE) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?
SRCEPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
MSC Industrial (MSM)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
MSMPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will Novo Nordisk's Rare Disease Bets Reduce GLP-1 Reliance?
by Ahan Chakraborty
NVO is expanding into rare blood disorders like hemophilia to ease reliance on GLP-1 drugs Ozempic and Wegovy.
NVONegative Net Change MRKNegative Net Change LLYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Novartis' Cosentyx Misses Primary Goal in Arteritis Phase III Study
by Zacks Equity Research
NVS' Cosentyx fails to meet its primary goal in a phase III study for giant cell arteritis, despite favorable safety data.
NVSNegative Net Change BAYRYNegative Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Hancock Whitney (HWC) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
HWCPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross?
by Zacks Equity Research
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
IONSNegative Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
UBS (UBS)'s Technical Outlook is Bright After Key Golden Cross
by Zacks Equity Research
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
UBSPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Will The Decline in Legacy Drugs Pull Down BMY's Top Line?
by Zacks Equity Research
Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer growth portfolio.
BMYNegative Net Change PFEPositive Net Change MRKNegative Net Change
biotechnology biotechs medical pharmaceuticals
FDA Grants Accelerated Approval to Regeneron's Blood Cancer Drug
by Zacks Equity Research
REGN scores FDA approval for Lynozyfic in tough-to-treat multiple myeloma, bolstering its oncology pipeline amid Eylea headwinds.
REGNNegative Net Change NVSNegative Net Change RHHBYNegative Net Change BAYRYNegative Net Change
biotechnology biotechs medical pharmaceuticals
Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore
by Zacks Equity Research
EXEL, VRNA, ALKS, KNSA, and IMCR are gaining ground as biotech M&A heats up and innovation offsets macro uncertainty.
ALKSNegative Net Change EXELPositive Net Change VRNAPositive Net Change KNSAPositive Net Change
biotechnology biotechs
Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli
by Zacks Equity Research
APLS stock jumps after inking a $300M royalty deal with Sobi for Aspaveli, bolstering its cash position and pipeline prospects.
AGENPositive Net Change VRNAPositive Net Change APLSPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Can RXRX's AI-Based Approach Revolutionize the Drug Discovery Process?
by Ahan Chakraborty
Recursion Pharmaceuticals is transforming drug discovery with AI-driven RecursionOS, slashing costs and boosting development speed.
SDGRPositive Net Change RLAYPositive Net Change RXRXPositive Net Change
artificial-intelligence biotechnology biotechs medical pharmaceuticals
Should You Buy Melco Resorts (MLCO) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
MLCOPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment
by Ekta Bagri
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.
EXELPositive Net Change ALKSNegative Net Change VRNAPositive Net Change KNSAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Biogen Begins Phase III Felzartamab Study for Third Kidney Disease
by Zacks Equity Research
BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
BIIBNegative Net Change AGENPositive Net Change VRNAPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Analog Devices (ADI) Now Trades Above Golden Cross: Time to Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
ADIPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Affiliated Managers Group (AMG) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Is it a good or bad thing when a stock experiences a golden cross technical event?
AMGPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines
Incyte Gains 9.2% in Three Months: Buy, Hold or Sell the Stock?
by Zacks Equity Research
INCY stock climbs 9.2% in three months as FDA approvals and a new diagnostic deal fuel pipeline momentum.
GSKNegative Net Change NVSNegative Net Change QGENNegative Net Change INCYPositive Net Change
biotechnology biotechs medical pharmaceuticals
Company News for Jul 1, 2025
by Zacks Equity Research
Companies In The News Are: META, MRNA, HOOD, AAPL.
AAPLPositive Net Change MRNAPositive Net Change METAPositive Net Change HOODNegative Net Change
biotechnology finance social-media tech-stocks
RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome
by Zacks Equity Research
Ultragenyx Pharmaceuticals' GTX-102 earns FDA Breakthrough status after early data shows sustained progress in Angelman syndrome patients.
BAYRYNegative Net Change AGENPositive Net Change RAREPositive Net Change IMCRPositive Net Change
biotechnology biotechs medical pharmaceuticals
Should You Buy Digi Power X Inc. (DGXX) After Golden Cross?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
DGXXPositive Net Change
ad-tech artificial-intelligence automation autonomous-vehicles batteries biotechnology cell-therapy creator-economy crispr daily-movers dna-sequencing electric-vehicles fin-tech furniture-retailers gambling gene-editing gene-therapy genetic-testing genomics home-builder home-buying-apps immuno-therapy iot medical-devices messenger-rna mobile moving-average-crossover oncology-screening payments ride-hailing robotics saas self-driving-cars smart-health social-media stock-price-movement stocks-moving-today vaccines